PIPERACILLIN-TAZOBACTAM (piperacillin sodium/tazobactam sodium)

There are 0 contraindications.

There are 5 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min
Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
Chronic kidney disease stage 5 (failure) GFr<15 ml/min
Clostridioides difficile infection
Severe neutropenic disorder

There are 3 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
Hypokalemia
Increased risk of bleeding due to coagulation disorder
Seizure disorder

There are 41 severe adverse reactions.

More Frequent	Less Frequent
None.	Anaphylaxis Phlebitis after infusion Pruritus of skin Skin rash Urticaria

Rare/Very Rare

Acute generalized exanthematous pustulosis Agranulocytosis Anemia Clostridioides difficile infection DRESS syndrome Eosinophilia Eosinophilic pneumonia Erythema multiforme Exfoliative dermatitis Hemolytic anemia Hemophagocytic lymphohistiocytosis Hepatitis Hyperbilirubinemia Hypersensitivity drug reaction Hypoglycemic disorder Hypotension Increased alanine transaminase Increased alkaline phosphatase Increased aspartate transaminase Increased risk of bleeding due to coagulation disorder Interstitial nephritis Jaundice Leukopenia Linear immunoglobulin A bullous dermatosis Muscle relaxation Neutropenic disorder Pancytopenia Qualitative platelet disorder Renal failure Rhabdomyolysis Seizure disorder Stevens-johnson syndrome Thrombocytopenic disorder Thrombocytosis Thrombophlebitis Toxic epidermal necrolysis

There are 20 less severe adverse reactions.

More Frequent	Less Frequent
Constipation Diarrhea Headache disorder Insomnia Nausea	Acute abdominal pain Candidiasis Fever Vomiting

Rare/Very Rare
Anticholinergic toxicity Arthralgia Chills Delirium Dyspepsia Epistaxis Flushing Injection site sequelae Myalgia Purpura Stomatitis

Available human data regarding use of piperacillin/tazobactam during pregnancy are inadequate to inform a drug-associated risk for major birth defects and miscarriage. Piperacillin and tazobactam both cross the human placenta. Reproduction studies in pregnant mice and rats using IV piperacillin/tazobactam (up to 1-2 times the human dosage of piperacillin and 2-3 times the human dosage of tazobactam based on body surface area) did not reveal evidence of teratogenicity or fetal structural abnormalities; however, intraperitoneal administration in rats at doses less than the maximum recommended human daily dosage based on body surface area given prior to mating and throughout gestation or from gestation day 17 through lactation day 21 resulted in maternal toxicity, reduced litter size, and effects on peri- and postnatal development (e.g., reduced pup weights, increased stillbirths, increased pup mortality, ossification delays, rib variations).

Piperacillin is distributed into human milk; it is not known whether tazobactam is distributed into human milk. Effects of the drugs on breast-fed infants or milk production are not known. The developmental and health benefits of breast-feeding should be considered along with the woman's clinical need for piperacillin/tazobactam and potential adverse effects on the breast-fed infant from the drug or from the underlying maternal condition.

No enhanced Geriatric Use information available for this drug.